Aspirin linked to stopping breast cancer development

Aspirin has always been strongly linked to cancer survival rates and a study published in 2010 revealed that the common and cheap painkiller, taken several times a week, reduced the risk of breast cancer death and the risk of cancer spreading, in women treated for early-stage breast cancer.

Now a new research study on more than 80,000 women, has once again linked aspirin and similar painkillers to cancer, but this time they say that taking aspirin can halve the risk of developing breast cancer, as aspirin is believed to block the effects of proteins involved in inflammation process and preventing the creation and proliferation of resistant stem cells.

The latest findings report that women taking the nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen could cut the risk of breast cancer development to one in 20. It has also emerged that Ibuprofen was more effective than aspirin and that long term use reduced the risk by 50 per cent compared with the 21 per cent of aspirin.

Dr Randall Harris, who led the latest study at Ohio State University said, 'Evidence clearly suggests a woman can reduce her chance of developing breast cancer by a regular intake of non-steroidal anti-inflammatory drugs such as aspirin and ibuprofen.'

He also added: 'Women over 40 might consider taking a standard dose of one of these compounds on a daily basis” but also warned that 'If they do, they should advise their doctor because there is a low risk of side-effects.'

The side effects of prolonged use of aspirin and ibuprofen are gastro-intestinal bleeding, ulcers and it can also trigger asthma attacks.

The study involved 80,741 post-menopausal women aged between 50 and 79 with no reported history of cancer and also took into account other factors such as age, family history, weight and exercise.

United Kingdom - Excite Network Copyright ©1995 - 2022